Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.338
Sell
RSI(14)
41.911
Neutral
STOCH(KDJ)(9,3,3)
41.478
Buy
ATR(14)
0.469
High Vlolatility
CCI(14)
-36.793
Neutral
Williams %R
82.057
Oversold
TRIX(12,20)
-0.492
Sell
StochRSI(14)
47.159
Sell
Search
Solid Biosciences Inc
SLDBAdd to Watchlist
8.050USD
-0.440-5.18%
Close 07-31 16:00（ET）Quotes delayed by 15 min
792.08MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-5.18%
5 Days
+2.81%
1 Month
-19.42%
6 Months
+24.61%
Year to Date
+42.73%
1 Year
+17.69%
Key Figures
8.480Open
8.480High
1.06MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
1.08%Turnover Ratio
8.490Prev. Close
8.000Low
6.01MTurnover
LossP/E Static
2.12P/B
0.00%Div Yield TTM
-50.02%ROA
8.86652wk High
1.00Volume Ratio
-124.70MNet Profit
98.39MShares
-1.9167EPS TTM
2.43Beta
-57.37%ROE
3.06552wk Low
5.65%Amplitude
100.00%Gross Margin
792.08MMarket Cap
-4.76Reward/Risk
4.55%Risk Rate
TradingKey Stock Score of Solid Biosciences Inc
Currency: USD Updated: 2026-07-31Key Insights
Solid Biosciences Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 72 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 18.50.In the medium term, the stock price is expected to trend up.Despite a very weak stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Solid Biosciences Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Neutral
Solid Biosciences Inc Highlights
StrengthsRisks
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 0.00.
Undervalued
The company’s latest PE is -4.21, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 83.89M shares, decreasing 14.08% quarter-over-quarter.
Held by Bill Nygren | OAKMX
Star Investor Bill Nygren | OAKMX holds 333.33K shares of this stock.
Analyst Rating
Based on
14
analysts
Buy
Current Rating
18.500
Target Price
+130.10%
Upside Space
Solid Biosciences Inc News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
14
analysts
Buy
Current Rating
18.500
Target Price
+130.10%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
Solid Biosciences Inc
SLDB
14
Beigene Ltd
ONC
27
IQVIA Holdings Inc
IQV
26
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
8.090
Sell
MA10
8.127
Sell
MA20
9.139
Sell
MA50
8.285
Sell
MA100
7.909
Buy
MA200
6.797
Buy
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Solid Biosciences Inc Info
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.
Ticker SymbolSLDB
CompanySolid Biosciences Inc
CEOCumbo (Alexander)
Websitehttps://www.solidbio.com/
Shareholders
Related Instruments
-0.53%
+0.23%
-1.00%
-2.54%
+0.33%
-1.44%
-0.61%
-0.79%
-8.78%
+0.48%
+0.70%
-1.00%
-0.69%
+0.49%
-1.08%
+3.32%
0.00%
+1.34%
-0.87%
-2.17%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.640
-24.790 (-7.43%)
200.760
+5.720 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of Solid Biosciences Inc (SLDB)?
The current price of Solid Biosciences Inc (SLDB) is 8.05.
What is the symbol of Solid Biosciences Inc?
The ticker symbol of Solid Biosciences Inc is SLDB.
What is the 52-week high of Solid Biosciences Inc?
The 52-week high of Solid Biosciences Inc is 8.87.
What is the 52-week low of Solid Biosciences Inc?
The 52-week low of Solid Biosciences Inc is 3.06.
What is the market capitalization of Solid Biosciences Inc?
The market capitalization of Solid Biosciences Inc is 792.08M.
Is Solid Biosciences Inc (SLDB) currently rated as Buy, Hold, or Sell?
According to analysts, Solid Biosciences Inc (SLDB) has an overall rating of Buy, with a price target of 18.50.
What is the Earnings Per Share (EPS TTM) of Solid Biosciences Inc (SLDB)?
The Earnings Per Share (EPS TTM) of Solid Biosciences Inc (SLDB) is -1.99.